This document discusses hypertrophic cardiomyopathy (HCM), a genetic heart condition characterized by thickening of the heart muscle. Key points include:
- HCM is caused by mutations in genes encoding sarcomere proteins and is inherited in an autosomal dominant pattern. The most common genetic causes are mutations in the MYH7 and MYBPC3 genes.
- HCM results in left ventricular hypertrophy and outflow tract obstruction. Other features include diastolic dysfunction, myocardial ischemia due to microvascular dysfunction, and ventricular arrhythmias.
- Risk factors for sudden cardiac death include a family history of sudden death, syncope, abnormal blood pressure response to exercise, ventricular arrhythmias on
Cardiac myxoma is a benign tumor, but it is known for its space-occupying effect at the site of origin and frequent systemic embolization. This case report highlights a biatrial myxoma of interatrial septum who presented with significant tricuspid valve regurgitation, atrial fibrillation, and cardioembolic stroke of the left parietal lobe, i.e., a biatrial myxoma with triple ripples.
Cardiac myxoma is a benign tumor, but it is known for its space-occupying effect at the site of origin and frequent systemic embolization. This case report highlights a biatrial myxoma of interatrial septum who presented with significant tricuspid valve regurgitation, atrial fibrillation, and cardioembolic stroke of the left parietal lobe, i.e., a biatrial myxoma with triple ripples.
Left ventricular non compaction is rare congenital cardiomyopathy with gaining interest due to advancement in imaging modalities for diagnosis and assessment of undulating phenotype
Left ventricular non compaction is rare congenital cardiomyopathy with gaining interest due to advancement in imaging modalities for diagnosis and assessment of undulating phenotype
Contemporary Perspectives on the Diagnosis and Management of Hypertrophic Car...asclepiuspdfs
Hypertrophic cardiomyopathy (HCM) is a cardiovascular disorder with genetic predisposition. The number of treatment modalities has grown in the contemporary era, with use of pharmacotherapy, device therapy, and surgical intervention, though with the relative paucity of data derived from randomized trials. Its clinical course and prognosis are relatively good. The ongoing quest is to establish the optimal treatment strategy in patients with HCM. This is of direct relevance in reducing the mortality burden associated with sudden cardiac death primarily secondary to dysrhythmias. This review summarizes the clinical features, course, and management of HCM. In particular, we highlight advances in cardiac magnetic resonance imaging assessment of HCM and how risk stratification criteria for suitability of implantable cardioverter defibrillators differ between continents.
Hypertrophic cardiomyopathy (HCM) is defined as hypertrophy of the myocardium more than 1.5 cm, without an identifiable cause . Other causes of left ventricular (LV) hypertrophy, such as long-standing hypertension, amyloidosis, and aortic stenosis must first be excluded before HCM can be diagnosed. As our understanding of the genetics of HCM continues to progress, the diagnosis of HCM will continue to incorporate information obtained from genetic testing, while also continuing to rely on transthoracic echocardiography (TTE) for the assessment of the phenotypic manifestations and the overall clinical severity of the disease.
CAD is the commonest cause of deaths worldwide. Mortality rates have declined over the past four decades in western countries however this condition remains responsible for ~one-third of all deaths in individuals over age 35.
Mortality is on the rise in Low and middle income countries Tanzania being among. The 2016 Heart Disease and Stroke Statistics update of the AHA reported that 15.5 million people in the USA. have CHD.
The reported prevalence increases with age for both women and men. For those US people, the lifetime risk of developing CHD with ≥2 major risk factors is 37.5% for men and 18.3% for women.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
2. GENETICS
• HCM is transmitted as a mendelian trait with an autosomal
dominant pattern of inheritance
• every offspring of an affected relative has a 50% chance of
developing the disease.
• HCM is now known to be caused by mutations in 11 or
more genes encoding proteins of the thick and thin
contractile myofilament components of the cardiac
sarcomere or the adjacent z disc
• Two sarcomere genes, those encoding β-myosin heavy
chain (MYH7) and myosin-binding protein C (MYBPC3),
are by far the most common, accounting for 30% of
consecutively screened patients with HCM and 70% of
those successfully genotyped.
• The troponin T gene (TNNT2) and several others are each
responsible for up to 5% of cases
3. ROLE OF GENETIC TESTING
• Rapidly automated DNA sequencing now provides opportunities for
comprehensive commercially available genetic testing
• To date, the greatest power of molecular testing currently lies with the
capability to identify or exclude affected status in family members without LV
hypertrophy
• Genetic testing can, however, clarify diagnosis for patients with metabolic and
storage disorders in which clinical presentation and pattern of LV hypertrophy
mimic those in sarcomeric HCM, but in which pathophysiology, natural history,
and management are dissimilar, including Fabry disease, PRKAG2, and LAMP2
(Danon’s disease).
• LAMP2 cardiomyopathy is associated with a lethal natural history refractory to
defibrillation therapy (with survival uncommon beyond 25 years), necessitating
early recognition and heart transplantation,
• whereas enzyme replacement therapy is available for patients with Fabry
disease.
4. VARIENTS
• Typically, one or more regions of LV chamber are
of greater thickness than other areas, often with
sharp transition in thickness between adjacent
areas or noncontiguous patterns of segmental
hypertrophy
• extension into the right ventricle in some patients.
• No single morphologic form of HCM is considered
“classic” or typical, and none are consistently
related to outcome.
5. TIME OF PHENOTYPIC AFFECTION
• LV hypertrophy may evolve in a dynamic fashion.
• Usually, the HCM phenotype remains incomplete until adolescence,
when accelerated growth and maturation are accompanied by
spontaneous (often striking) increases in LV wall thickness and more
extensive distribution of hypertrophy.
• These structural changes may occasionally be delayed until mid-life or
even later (late-onset adult LV hypertrophy)
• Genetically affected family members without LV hypertrophy (gene-
positive, phenotype-negative, reflecting incomplete penetrance)may
show ancillary signs of disease:
1. Subclinical diastolic dysfunction,
2. blood-filled myocardial crypts
3. mitral leaflet elongation
4. collagen biomarkers and
5. myocardial scarring or
6. 12-lead ECG abnormalities that may precede the appearance of LV
hypertrophy.
6. Mitral Valve Apparatus
• Primary structural abnormalities of the mitral
apparatus responsible for LV outflow obstruction
are part of HCM phenotypic expression
1. The mitral valve may be more than twice
normal size as a consequence of elongation of
both leaflets, or segmental enlargement of only
the anterior leaflet or mid-scallop of the
posterior leaflet.
2. congenital and anomalous anterolateral
papillary muscle insertion directly into anterior
mitral leaflet (without interposition of chordae
tendineae) may occur.
7. Histopathology
• In HCM, hypertrophied cardiac muscle cells
(myocytes) in both ventricular septum and LV free
wall exhibit bizarre shapes, often maintaining
intercellular connections with several adjacent cells.
• Many myocytes (and also myofilaments) are
arranged in chaotic and disorganized architectural
patterns .
• Areas of cell disarray are evident in 95% of HCM
hearts at autopsy, usually occupying substantial
portions of hypertrophied (as well as
nonhypertrophied) LV myocardium (i.e., 33% of
septum and 25% of free wall).
8. Histopathology
• At autopsy, the vast majority of patients with HCM
exhibit intramural coronary arterioles with marked
thickening of the vessel wall secondary to smooth
muscle hyperplasia in the media (associated with
abundant disorganized elastic fibers), causing
deformation and narrowing of the lumen and
frequently located within or close to areas of
myocardial scarring.
• This microvascular small-vessel disease probably is
responsible for repeated bursts of clinically silent
myocardial ischemia leading to myocyte death, with a
repair process in the form of replacement (and often
transmural) myocardial fibrosis
• In addition, volume of the interstitial (matrix) collagen
compartment, constituting the structural LV
framework, is greatly expanded.
9. Consequence(PATHOPHYSIOLOGY OF VT IN HCM)
• It is likely that the interplay of disorganized
cellular architecture, microvascular ischemia,
and replacement fibrosis impairs transmission of
electrophysiologic impulses and predisposes to
disordered patterns and increased dispersion of
electrical depolarization and repolarization.
• This, in turn, serves as an electrophysiologically
unstable substrate and a trigger for REENTRY
VENTRICULAR ARRTHMIAS
11. Pathophysiology LVOTO
• SUB AORTIC OBSTRUCTION IN HCM represents true mechanical
impedance to LV outflow, producing markedly increased intraventricular
pressures that over time may be detrimental to LV function, probably by
increasing myocardial wall stress and oxygen demand .
• In the vast majority of patients, obstruction is produced in the proximal
LV BY SYSTOLIC ANTERIOR MOTION (SAM) of the mitral valve in which
elongated leaflets bend sharply at 90 degrees and contact the septum
in midsystole owing to a drag effect—that is, hydrodynamic pushing
force of flow directly on the leaflets
• The MAGNITUDE OF THE OUTFLOW GRADIENT, which is reliably
estimated with continuous wave Doppler, is directly related to the
duration of mitral valve–septal contact.
• Mitral regurgitation is a secondary consequence of SAM, with the jet
(usually mild to moderate in degree) directed posteriorly
• Occasionally, intraventricular obstruction may occur at mid-cavity level
caused by systolic contact of septum with a papillary muscle that is
anomalously positioned and may insert directly into anterior mitral
leaflet This form of obstruction may be associated with LV apical
aneurysm.
12. PATHOPHYSIOLOGY OF MR
• Mitral regurgitation is a secondary
consequence of SAM, with the jet (usually
mild to moderate in degree) directed
posteriorly
• Marked and centrally located mitral
regurgitation jets usually suggest an intrinsic
valve abnormality (e.g., with myxomatous
degeneration).
13. DIASTOLIC DYS(CAUSES)
• Reduced ventricular compliance in HCM
probably results largely from those factors
determining passive elastic properties of the
LV
1. hypertrophy,
2. replacement scarring,
3. Interstitial fibrosis, and
4. disorganized cellular architecture.
14. Microvascular Dysfunction
• Myocardial ischemia due to microvascular dysfunction
appears to be an important pathophysiologic component of
the HCM disease process, promoting adverse LV
remodeling and ultimately affecting clinical course.
• Marked reduction in coronary reserve can be
demonstrated in patients with HCM using positron
emission tomography (PET) early in the clinical course (in
both hypertrophied and nonhypertrophied regions of the
left ventricle) and is an important determinant of
prognosis, including progressive heart failure, systolic
dysfunction, and long-term cardiovascular mortality.
• PET represents the technique of choice for the assessment
of microvascular function in patients with HCM, although
its systematic use has not entered clinical practice
systematically
15. PRINCIPAL DETERMINANTS OF PROGRESSIVE
HEART FAILURE
• The principal determinants of progressive heart failure and
heart failure–related death in HCM are
1. LV outflow obstruction,
2. atrial fibrillation, and
3. diastolic dysfunction,
4. SCARRING DUE TO MICROVASULAR ISCHEMIA
• each alone or in combination.
• However, in contrast with sudden death risk (which is
related to particularly marked LV hypertrophy),
• greater LV wall thickness ----is not associated with an
increased likelihood of progressive heart failure
symptoms.
16. HF IN HCM
• Approximately 3% of patients with HCM develop advanced
(endstage) heart failure associated with systolic dysfunction
(ejection fraction <50%), a consequence of
1. small vessel–mediated myocardial ischemia and
2. diffuse transmural scarring,
MOST RELIABLE RISK MARKER FOR EVOLUTION TO THE END STAGE is
in fact a family history of HCM with systolic dysfunction.
• This profound form of heart failure is associated with LV remodeling
including wall thinning, chamber enlargement, or both, as well as
with atrial fibrillation.
• The end stage, with unrelenting heart failure symptoms, is
virtually the sole indication for heart transplantation in
• Survival after transplantation in HCM is similar to (or possibly more
favorable than) that in other cardiac diseases (75% at 5 years, 60%
at 10 years
17. Sudden death in HCM
• Sudden death in HCM may occur at a wide range
of ages, most commonly in adolescents and
young adults before the age of 30 to 35 years.
• the potential for lethal ventricular
tachyarrhythmias is mitigated at more advanced
ages (even in the presence of conventional risk
markers)
• Indeed, in older patients, morbidity and
mortality is largely unrelated to HCM, and more
frequently the consequence of other cardiac or
noncardiac comorbid diseases.
18. RISK MARKERS FOR PRIMARY
PREVENTION(PRPHYLACTIC ICD)
risk markers include one or more of the following, which
assume greater weight in younger patients (<50 years of age)
• (1) family history of one or more premature HCM-related
deaths, particularly if sudden and multiple;
• (2) unexplained syncope, especially if recent;
• (3) hypotensive or attenuated blood pressure response to
exercise;
• (4) multiple, repetitive (or prolonged) nonsustained bursts
of ventricular tachycardia on serial ambulatory ECGs;
• (5) massive LV hypertrophy (wall thickness, ≥30 mm)
EXTENSIVE LATE GADOLINIUM ENHANCEMENT ON
CONTRAST CMR imaging (occupying 15% or more of LV mass)
has been shown to be an independent predictor of sudden
death, even in the absence of conventional risk factors,
leading to consideration of prophylactic ICDs
19.
20.
21.
22. OTHER RISK FACTORS
1. THIN-WALLED AKINETIC LV APICAL ANEURYSMS WITH
REGIONAL MYOCARDIAL SCARRING
2. COEXISTENT OBSTRUCTIVE ATHEROSCLEROTIC CORONARY
ARTERY DISEASE, (CAD)
3. MARKED LV OUTFLOW OBSTRUCTION AT REST,(LVOTO)
4. END-STAGE PHASE (AS A BRIDGE TO HEART
TRANSPLANTATION),
5. PERCUTANEOUS ALCOHOL SEPTAL ABLATION WITH
TRANSMURAL INFARCTION IN SELECTED PATIENTS
6. MULTIPLE SARCOMERE MUTATION
7. AS WELL AS EXTENSIVE LATE GADOLINIUM ENHANCEMENT
prognosis appears to be benign in gene carriers without LV
hypertrophy, with little evidence to justify disqualification of such
family members from most competitive sports or employment
opportunities, or prophylactic ICDs
23.
24. Clinical parameters that favor the diagnosis of HCM in
trained athletes
1. Identification of a disease-causing sarcomeric
protein mutation
2. recognition of HCM in a relative;
3. transmitral Doppler waveform consistent with
altered LV relaxation and filling (DIASTOLIC
DYSFUNCTION)
4. LV END-DIASTOLIC CAVITY dimension less than
45 mm
5. LATE GADOLINIUM ENHANCEMENT on CMR
imaging.
6. NO REGRESSION OF LVH WITH DECONDITIONING
25. SCREENING IN FAMILY
• Screening evaluations usually are performed on a 12- to 18-month basis,
beginning at the age of 12 years.
• If these studies do not show LV hypertrophy by the time full growth is
achieved (at 18 to 21 years of age), it is likely that an HCM-causing
mutation is absent.
• However, morphologic conversion to the HCM phenotype (i.e., with LV
hypertrophy) can be delayed well into adulthood. Therefore it is not
possible to provide complete reassurance that a normal echocardiogram
at maturity unequivocally defines genetically unaffected status.
• In selected clinical circumstances, it may be prudent to extend
echocardiographic surveillance into adulthood at 5-year intervals, or to
pursue definitive genetic testing.
• When a mutation regarded as pathogenic has been identified in the
proband………. the absence of this mutation may exclude a relative from
further clinical evaluations. However, this strategy is not advisable in the
presence of variants of unknown significance.
26.
27. Bacterial endocarditis PROPHYLAXIS
IN HOCM
• Bacterial endocarditis is an uncommon but profound
complication of HCM (prevalence <1%) and is almost
always confined to patients with LV outflow
obstruction.
• Vegetations most commonly involve
1. anterior mitral leaflet or
2. septal endocardium at the site of mitral valve contact.
Prevention of bacterial endocarditis by antimicrobial
prophylaxis remains a prudent strategy before dental
or surgical procedures, particularly for patients with
HCM associated with outflow obstruction
28. INDICATION OF SURGERY
1. Patients with resting or provocable gradients
greater than 50 mm Hg
2. who continue to experience significant
functional limitation (i.e., NYHA class III-IV)
due to limiting symptoms of exertional
dyspnea, chest pain, or recurrent syncope
despite maximal medical therapy
may be considered candidates for surgical
therapy
29. Surgical therapy is not currently
recommended
1. for patients who are without significant outflow
tract obstruction,
2. for those who have relatively mild symptoms
with obstruction,
3. to treat associated complications of this
condition (e.g., AF, syncope)
30. SEPTAL MYETOMY-MORROW PROCEDURE
• The “gold standard” septal myectomy, described by
Morrow, is performed via an aortotomy so that the
proximal septum is approachable via the aortic valve.
• Between 5 to 15 g of myocardial tissue is resected, from
the base of the aortic valve to a region distal to the mitral
leaflets, such that the area of mitral-septal contact that
results in SAM is removed and the LVOT is enlarged.
• Because it is of critical importance to correctly identify the
involved portion of the ventricular septum and to resect
enough myocardium to relieve the outflow tract gradient,
most experienced centers employ transesophageal
echocardiography (TEE) to assist in localizing the desired
region for resection and to monitor the effect of resection
on the gradient intraoperatively.
31. ALTERATION IN THE CLASSIC MORROW PROCEDURE
• in which an extended myectomy is combined with
• partial excision and mobilization of the papillary
muscles,
which results in amelioration of the outflow tract
obstruction,
reduced tethering of the subvalvular mitral
structures
a more individualized surgical resection
depending on the extent and location of the
patient’s LVH. .
32. PATIENTS WITH SPECIFIC COMORBIDITIES
• In patients with specific comorbidities, such as
AF or coronary artery disease, myectomy may
be combined with adjunctive surgical
procedures such as the
maze procedure to treat AF or
coronary bypass grafting
33. Mitral valvular abnormalities IN HCM
• Mitral valvular abnormalities, such as elongated and
flexible leaflets, substantially contribute to the degree
of outflow tract obstruction in an important minority
of patients.
• These patients often benefit from mitral valve
plication at the time of myectomy to more effectively
reduce the degree of outflow tract obstruction that
results from SAM and to reduce the associated mitral
regurgitation.
• Mitral valve replacement is typically reserved for
patients
with significant primary valvular abnormalities such as
myxomatous degeneration leading to mitral valve
prolapse or regurgitation
34. COMPLICATION
• The modern-day septal myectomy procedure
carries a relatively low operative risk due to
continued technical refinement, with a
• cumulative operative mortality rate of
approximately 1% to 3% overall
• Left bundle branch block (LBBB) after myectomy
is understandably very common because of the
location of the procedure.
• Complete heart block requiring implantation of a
permanent pacemaker
• iatrogenic formation of a ventricular septal defect
35. SURGERIES IN HCM
• MORROWS EXTENDED MYECTOMY(MYECTOMY
WITH MV PLICATION)
• PAPILLARY MUSCLE REPAIR
• MV REPAIR OR REPLACEMENT
• MAZE PROCEDURE
• ALONG WITH CABG
36. SEPTAL ABLATION INDICATION (PT SELECTION CRITERIA)
1.Severe heart failure symptoms (i.e., NYHA class III-IV) despite maximal
medical therapy
2.Septal thickness >18 mm
3.Subaortic gradient >50 mm Hg (resting or with provocation) due to mitral-
septal contact
4.Absence of papillary muscle or mitral valvular anomalies (i.e., anomalous
papillary muscle insertion)
5.Absence of significant coronary arterial disease
6.Compatible septal perforator branch arterial anatomy
7.Relative contraindications to surgical myectomy (i.e., age, comorbidity)*
37. SEARCH FOR ABNORMALITIES THAT ARE BETTER ADDRESSED
SURGICALLY
• Such abnormalities include -
anomalous papillary muscle insertion into the mitral valve,
anatomically abnormal mitral valve with a long
anteroposterior leaflet,
coexistent coronary artery disease,
primary valvular disease (aortic or mitral),
subaortic membrane or pannus, none of which would be
adequately addressed by septal ablation.
Abnormally elongated and flexible anterior mitral leaflets
resulting in an anterior location of the coaptation line and
outflow tract obstruction also are not correctable via
catheter-based techniques and require surgical myectomy
with plication.
In addition, many experienced centers refer patients with a
septal thickness greater than 2.5 cm for surgical correction.
38. INVASIVE CONFIRMATION OF SIGNIFICANT LVOT
GRADIENT(TECHNIQUE)
• Given the fact that most cases of HOCM are diagnosed
noninvasively with echocardiography and, often, no invasive
hemodynamic studies have been performed before ablation,
• many operators reconfirm the presence of significant LVOT
obstruction by positioning an end-hole catheter in the
ventricular apex and recording a slow pullback under
fluoroscopic guidance.
• Alternatively, simultaneous measurement of the ascending
aortic and intracavitary pressures may be obtained via the
placement of an ascending aortic catheter and an end-hole
catheter as described earlier.
• If an LVOT gradient is not confirmed under basal or resting
conditions, provocation with amyl nitrate or the Valsalva
maneuver may be attempted.
• Failure to confirm a significant gradient after these maneuvers
should prompt the operator to further pursue alternative
etiologies for the patient’s symptom complex.
39. • A visual assessment of the contour
of the aortic (Ao) and left ventricular
(LV) pressures is important during
cardiac catheterization.
• Left, Patients with fixed obstruction
(either valvular stenosis or fixed
subvalvular stenosis) will
demonstrate a parvus and a tardus
in the upstroke of the aortic
pressure, beginning at the time of
aortic valve opening.
• Right, In patients with a dynamic
obstruction (such as that found in
hypertrophic cardiomyopathy), the
aortic pressure will rise rapidly at
the onset of aortic valve opening
and then develop a spike-and-dome
contour as the obstruction occurs in
late systole. The left ventricular
pressure also has a late peak
because of the mechanism of this
dynamic obstruction. LA indicates
left atrium.
40. • Response of the aortic pressure
after a long pause is useful in
differentiating between the fixed
obstruction of valvular aortic
(Ao) stenosis and the dynamic
obstruction of hypertrophic
cardiomyopathy.
• A, In this patient with valvular
aortic stenosis, the beat after the
premature ventricular contraction
(PVC) has an increase in pulse
pressure (P-P).
• B, In this patient with
hypertrophic cardiomyopathy,
there is a reduction in the pulse
pressure on the beat after the
premature ventricular
contraction. LV indicates left
ventricle; LA, left atrium.
41. Patients with hypertrophic cardiomyopathy
may have labile left ventricular (LV) outflow
tract gradients.
If septal reduction therapy is to be
considered, there must a gradient of >50
mm Hg either at rest or during provocation.
Exercise would be the optimal physiological
mechanism to provoke a labile obstruction
but is difficult in the catheterization
laboratory.
Isoproterenol infusion is an excellent
method to simulate exercise by stimulating
both B1 and B2 receptors.
Left, There is no left ventricular outflow
gradient at rest.
Middle, With initial infusion of
isoproterenol, there is a 40-mm Hg gradient
across the left ventricular outflow tract.
Right, With a greater infusion of
isoproterenol, there is a 65-mm Hg left
ventricular outflow gradient
42.
43. SELECTION OF SEPTAL BR
• Standard diagnostic coronary cineangiography is performed as a first step
to clearly define the patient’s anatomy and to evaluate for concomitant
atherosclerotic disease.
• selection of the appropriate septal perforator branch through which to
perform the ablation. the camera should be positioned in the (RAO CR/AP
CR)
• It is also important to determine the septal vessel’s course along the
septum (i.e., on the right or left side), using the left anterior oblique (LAO)
projection.
• (SUB SELECTION OF SEPTAL BR) septal anatomy may vary such that one
subdivision runs along the left side of the septum and another runs
along the right.
• Selection of the left-sided subdivision is optimal for the ablation,
because there is a reduced likelihood of inducing complete heart block
during ethanol infusion.
• Most septal perforators arise from the LAD, substantial anatomic
variation has been described in which the vessels may arise from the left
main trunk, the ramus intermedius, the left circumflex artery, diagonal
branches, or even a branch of the right coronary artery
44. PROPHYLACTIC TPM PRIOR TO HAPARIN
• A temporary transvenous pacemaker is placed in
advance as a prophylactic measure in case of the
development of complete heart block during, or in
days after, the ablation.
• After successful placement of both the temporary
pacemaker and the arterial sheath, heparin is
administered to achieve an activated clotting time
of 250 to 300 seconds to prevent thrombosis in
guide catheters and on wires.
45. METICULOUS WHILE CHOOSING THE SEPTAL ARTERY
• After angiographic identification of the septal
arteries, close attention must be given to
1. vessel size,
2. angulation, and
3. the distribution of myocardial territories served
by the given vessel.
46. DIFFICULTY WITH ANGULATED VESSEL
• Angulation of the septal vessels, either at the
origin from the primary vessel (e.g., the LAD) or
at the bifurcation of a larger septal artery, is an
important consideration in vessel selection.
• Vessels with angulations greater than 90
degrees are often technically challenging and
result in difficulty passing the balloon into the
selected vessel, with frequent prolapse of the
wire into the mid-LAD.
• Specialized techniques using catheters that allow
control of the distal angle (Venture Catheter, St.
Jude Medical, St. Paul, MN) may be useful in
these circumstances.
47. VARIATION OF MYOCARDIUM SUBTENDED BY SEPTALS
• There is substantial variation in the distribution of blood flow supplied by
the septal perforators in patients with HOCM compared with the
unaffected population.
• In both autopsy and angiography studies, it has been demonstrated that
the first septal artery may provide blood flow to regions other than the
targeted basal septum (including the right ventricle);
• it may supply the basal septum incompletely and share this
responsibility with a second septal branch, or
• it may subtend a substantially larger distribution of myocardium than
would be expected.
• Therefore an intimate knowledge of the myocardial distribution of blood
flow supplied by the selected septal branch is essential to accurately
target the correct area for ablation and to avoid infarction of an
unanticipated region or an oversized infarction of the septum itself.
• This is most commonly accomplished during the procedure by the selective
injection of dye under cine guidance and the concomitant use of
transthoracic echocardiography (TTE) using injectable contrast material .
48. PROCEDURE
• After angiographic assessment of the septal anatomy, a guide
catheter providing extra support (such as a 6- or 7-Fr XB
catheter) is used to engage the left main trunk.
• Subsequently, a 0.014-inch extra support wire with a soft tip is
passed into the selected septal perforator branch, most
commonly the first septal perforator
• A short angioplasty balloon, usually 1.5 to 2 mm in diameter
and 10 mm in length, is passed over the guidewire and into the
septal branch. Difficulty in passing the balloon may be resolved
by use of a stiffer guidewire to provide greater support for
balloon placement.
• Care must be taken to seat the balloon deeply enough into the
septal artery and to fully expand the balloon to ensure that the
injected ethanol is not refluxed in to the LAD.
• Conversely, if the balloon is placed too deeply into the septal
vessel, the injected ethanol may spare the basal portion of the
septum, resulting in an unsuccessful procedure
49. TO VERIFY THE DISTRIBUTION OF MYOCARDIUM BEING SUPPLIED BY
THE SELECTED VESSEL
• It is essential at this point to verify the distribution of myocardium being
supplied by the selected vessel, given the substantial degree of variability
in the cardiac anatomy in this patient population.
• This can be accomplished by traditional angiography or TEE, often with
the aid of echocardiographic contrast.
• After correct positioning, as described earlier, the operator inflates the
balloon (typically to 10 to 12 atmospheres) to occlude the perforator, and
1 to 2 mL of contrast material is injected to assess the full extent of
myocardium supplied by the chosen vessel.
• Contrast should be injected slowly so as to mimic the anticipated alcohol
infusion.
• Extreme caution should be taken to verify that the infused contrast
material does not reflux into the LAD or into other coronary arteries
(e.g., the posterior descending artery), thus possibly exposing a large
amount of unintended myocardium to damage when the ethanol is
infused.
• Aggressive contrast infusion may overwhelm collateral vessels and create
an inferior LV wall infarction.
50. CONTRAST ECHO
• After angiographic confirmation of septal occlusion, further assessment of the septal
distribution is obtained via contrast echocardiography
• After careful inspection of the septum in the apical long-axis, four-chamber, and
parasternal long-axis views, 1 to 2 mL of Albunex contrast is injected into the septal branch
through a tuberculin-type syringe.
• Because Albumex, a first-generation echocardiographic contrast agent, is no longer
available in many countries, second- and third-generation agents are currently used.
These agents have proved to be suboptimal because they traverse the capillary beds
rapidly and produce a large amount of echocardiographic “shadowing” from the opacified
ventricles. Therefore, it is important to dilute these agents before injection. In our
laboratory, the contrast vials are typically opened 10 to 15 minutes before the time of
expected use so as to decrease their potency. The contrast is then further diluted with
sterile saline in a 1 : 5 or 1 : 10 mixture at the time of injection.
• Pulsed-wave Doppler echocardiography is the imaging method of choice in using the
diluted contrast material to avoid destruction of the microbubbles with the higher-
frequency continuous-wave ultrasound.
• This procedure allows the operator to verify that the chosen vessel primarily supplies the
proximal interventricular septum and not portions of the inferior wall, LV papillary
musculature, or right ventricular free wall via the moderator band.
• Ideally, contrast material will appear in the basal portion of septum responsible for the
greatest extent of septal-mitral contact.
• Appearance of contrast in the distal septum or other regions of myocardium is a
contraindication to ethanol infusion, because it can result in infarction of an undesired
territory or an infarction of unanticipated size.
51. CONTRAST ECHO
• As a final method of ensuring that the desired
area of myocardium has been selected, it is
recommended that the operator document a
greater than 30% reduction in the LVOT gradient
during balloon inflation.
• A rather rapid reduction in gradient can be
observed with prolonged balloon occlusion of a
septal perforator branch.
• Such an observation suggests that the correct
septal distribution has been targeted for ablation.
52. METHODS TO ASSURE CORRECT
SEPTAL IS CHOSEN
• CONTRAST ECHO
• greater than 30% reduction in the LVOT
gradient during balloon inflation
53. CHECKLIST BEFORE ETHANOL INJ
• Before proceeding with ethanol injection, it is
essential to confirm that the balloon has not
migrated during this process (CONTRAST ECHO) -
--This is easily done by fluoroscopic verification
and injection of another 1 to 2 mL of contrast
agent through the guide catheter.
• previously placed temporary pacemaker
continues to have a suitable pacing threshold.
54. ETHANOL INJ
• After confirmation of proper balloon positioning, the operator may
proceed with ethanol injection.
• Whereas most experienced centers use between 1 to 3 mL of desiccated
ethanol, this volume may be adjusted based on the appearance of the
septal anatomy and the degree of contrast washout.
• If there is rapid contrast washout due to collateralization of the septal
branch,
the rate and volume of ethanol infusion should be reduced to prevent the
alcohol from escaping to undesirable areas of myocardium via the
collaterals
• The ethanol is injected into the vessel over a 1- to 5-minute period with
the balloon remaining inflated.
• During the initial infusion, continued monitoring of the resting gradient is
essential to judge the efficacy of the procedure. In general, a
• reduction in the LVOT gradient to less than 30 mm Hg in the setting of a
resting gradient greater than 50 mm Hg, or a greater than 50% reduction
of a provocable gradient, is considered indicative of a successful
procedure in the catheterization laboratory
55. Successful procedure in the
catheterization laboratory
• REDUCTION IN THE LVOT GRADIENT TO LESS
THAN 30 MM HG IN THE SETTING OF A
RESTING GRADIENT GREATER THAN 50 MM
HG
• GREATER THAN 50% REDUCTION OF A
PROVOCABLE GRADIENT
56. PROCEDURE
• Before the balloon is disengaged from the septal vessel, it is
recommended that the guidewire be placed again into the
septal branch for smooth removal of the balloon and
maintenance of access across the left main trunk and the
LAD.
• As a final step, angiography of the LAD and septal vessels
is performed to verify the integrity of the coronary
circulation. Phasic flow may be observed in the injected
septal branch immediately after the ablation, although
total occlusion is frequently observed.
• The amount of induced myocardial tissue destruction often
results in elevation of the enzyme creatinine
phosphokinase (CPK) to levels between 800 and 1200 U/L,
• The transvenous pacing wire may be discontinued 48 hours
after the procedure if there is an absence of
bradyarrhythmia or heart block that would require
continued observation or a permanent pacemaker
57. CAG AFTER ETHANOL INJ
• As a final step, angiography of the LAD and
septal vessels is performed to verify the
integrity of the coronary circulation.
Phasic flow may be observed in the injected
septal branch immediately after the ablation,
although total occlusion is frequently
observed.
58. Complication(INTRAPROCEDURAL)
• The complication rate after septal ablation is relatively low and is comparable to
that of septal myectomy.
• As opposed to the LBBB so commonly observed after septal myectomy, a right
bundle branch block (RBBB) is observed in up to 80% of patients who have
undergone ablation.
• The incidence of complete heart block has decreased in recent years and now
ranges from 5% to 40%, with an average value of 12% to 15% at experienced
centers. The presence of a preexisting LBBB and a rapid bolus injection of
ethanol during ablation have both been positively correlated with an increased
incidence of high-degree atrioventricular block requiring permanent pacemaker
implantation.
• Extravasation of alcohol into the LAD during infusion is a rare but catastrophic
complication that often results in a large infarction of the middle to distal
anterior wall and is clearly associated with increased mortality.
• Coronary dissection caused by the extra support guidewire or the catheter has
been reported in rare instances.
• Tamponade due to perforation of the right ventricular apex during insertion of a
transvenous pacing wire or during interatrial septal puncture for periprocedural
hemodynamic monitoring has also been reported.
• Overly extensive infarction of the interventricular septum as a result of too
generous a quantity of infused alcohol or too rapid an infusion rate during
ablation can result in a ventricular septal rupture.
59. VT AFTER SEPTAL ABLATION
• Ventricular arrhythmias can be seen both during and up to
48 hours after the procedure, but this complication is rare
and usually does not require prolonged therapy.
• Unlike myectomy, septal ablation results in the formation
of a large intramyocardial scar that may serve as substrate
for future malignant ventricular arrhythmias.
• There has been some conjecture that this could result in an
increased risk of late arrhythmic mortality, especially in
younger patients undergoing ablation.
• Patients should be observed closely for recurrence of
symptoms or any arrhythmia.
• ICD implantation should be considered if there is evidence
of nonsustained VT, but this is extremely rare.
60. FOLLOW UP
• Objective assessment of functional capacity
using exercise testing is appropriate for
monitoring these patients.
• Repeat alcohol ablation may be considered if
symptoms recur and an appropriate septal
perforator is available for injection.
• If repeat ablation is not feasible, surgical
myectomy may need to be considered in this
group.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72. MECHANISM OF MR IN HOCM
• The mechanism of MR in HOCM is attributed to the following .
1. Asymmetric septal hypertrophy (ASH ) related abnormal pap muscle
alignment (Geometric distortion )
2. Exaggerated SAM(AML is attracted towards LVOT with every systole
that tend to keep the mitral valve unguarded and MR results)*
3. Intrinsic abnormalities of mitral valve.
4. Associated MVPS
5. VPDs and Non-sustained VT can result in transient MR
6. Pacemaker mediated MR (DDD pacemaker was used to induce
desynchrony of LVOT vs LV free wall .This concept is almost a
failed one now !)
7. End stage HOCM -Left ventricular dilatation
• * This mechanism is considered less important , as SAM is almost
universal in HOCM but MR occurs in less than 20% patients with
HOCM.
73. • LVOT jet is different from MR
jet in size, shape, timing and
site of maximum signal . Still it
is often be confused with one
other. Most common reason
for this is technical .
• A careful apical 4 chamber
view with well opened LVOT
will reduce the error .
• Never record a HOCM echo
without ECG gating .
• The MR jet may be very trivial
in color flow but doppler will
still pick the signal well .
• Realise ,for hemodyanmic
reasons MR jet must be always
more than LVOT jet.Finally if
you get a report a LVOT
gradient > 100mmhg in HOCM
suspect it to be MR ! More
often your suspicion will prove
to be right